IRIS
Mancuso, Maria Elisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.339
NA - Nord America 1.110
SA - Sud America 496
EU - Europa 266
Continente sconosciuto - Info sul continente non disponibili 106
AF - Africa 36
Totale 3.353
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.037
SG - Singapore 608
BR - Brasile 392
VN - Vietnam 330
CN - Cina 242
IT - Italia 122
AR - Argentina 50
HK - Hong Kong 41
ID - Indonesia 39
FR - Francia 28
DE - Germania 24
CA - Canada 22
BD - Bangladesh 19
EC - Ecuador 19
GB - Regno Unito 18
MX - Messico 17
FI - Finlandia 13
IQ - Iraq 12
MQ - Martinica 11
RU - Federazione Russa 10
VE - Venezuela 10
CO - Colombia 9
UA - Ucraina 9
IE - Irlanda 7
NL - Olanda 7
AT - Austria 6
EG - Egitto 6
ZA - Sudafrica 6
IN - India 5
JM - Giamaica 5
MY - Malesia 5
PK - Pakistan 5
PL - Polonia 5
TN - Tunisia 5
TR - Turchia 5
CL - Cile 4
HN - Honduras 4
IL - Israele 4
JP - Giappone 4
MA - Marocco 4
NG - Nigeria 4
PY - Paraguay 4
SE - Svezia 4
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
KE - Kenya 3
LT - Lituania 3
NI - Nicaragua 3
OM - Oman 3
PE - Perù 3
SN - Senegal 3
UY - Uruguay 3
UZ - Uzbekistan 3
BO - Bolivia 2
CR - Costa Rica 2
GT - Guatemala 2
MD - Moldavia 2
NP - Nepal 2
SV - El Salvador 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
ES - Italia 1
ET - Etiopia 1
HR - Croazia 1
KH - Cambogia 1
KR - Corea 1
LB - Libano 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 3.247
Salva come PNG Salva come JPEG
Città #
Singapore 170
San Jose 147
Ashburn 137
Beijing 123
Ho Chi Minh City 120
Council Bluffs 102
Dallas 88
Hanoi 64
Santa Clara 45
Hong Kong 41
Milan 39
Wilmington 33
Los Angeles 32
The Dalles 25
São Paulo 22
Da Nang 17
Haiphong 17
Assago 16
New York 16
Chandler 15
Rome 15
Buffalo 13
Helsinki 13
Thái Bình 13
Curitiba 12
San Mateo 12
Fort-de-France 11
Ann Arbor 10
Phoenix 10
Rio de Janeiro 10
Thái Nguyên 10
Hải Dương 9
Jakarta 9
Brasília 8
Buenos Aires 8
Chicago 8
Mexico City 8
Shanghai 8
Guayaquil 7
Houston 7
Leawood 7
Orem 7
Porto Alegre 7
Princeton 7
Biên Hòa 6
Boardman 6
Can Tho 6
Dublin 6
Frankfurt am Main 6
Quincy 6
Toronto 6
Winston-Salem 6
Amsterdam 5
Baghdad 5
Belo Horizonte 5
Campinas 5
Dhaka 5
Hillsboro 5
Lawrence 5
Montreal 5
Ribeirão Preto 5
Uberlândia 5
Woodbridge 5
Atlanta 4
Austin 4
Benin City 4
Brooklyn 4
Cairo 4
Catania 4
Columbia 4
Contagem 4
Duque de Caxias 4
Ha Long 4
Istanbul 4
Johannesburg 4
Las Vegas 4
Manaus 4
Manchester 4
Millersburg 4
Nha Trang 4
Paris 4
Posadas 4
Quito 4
Sherwood 4
Silver Spring 4
Turin 4
Vila Velha 4
Warsaw 4
Anápolis 3
Bandung 3
Boston 3
Caxias do Sul 3
Cleveland 3
Columbus 3
Dakar 3
Figino 3
Fortaleza 3
Guarulhos 3
Itaquaquecetuba 3
Kingston 3
Totale 1.737
Salva come PNG Salva come JPEG
Nome #
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study 92
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 89
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy 70
Mortality and causes of death in Italian persons with haemophilia, 1990-2007 69
Uniportal and three-portal video-assisted thoracic surgery lobectomy: analysis of the Italian video-assisted thoracic surgery group database 63
Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A 63
What counts more: the patient, the surgical technique, or the hospital? A multivariable analysis of factors affecting perioperative complications of pulmonary lobectomy by video-assisted thoracoscopic surgery from a large nationwide registry 60
Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive Patients 59
Predicting a Prolonged Air Leak After Video-Assisted Thoracic Surgery, Is It Really Possible? 53
Severe hemophilia with mild bleeding phenotype : molecular characterization and global coagulation profile 51
Comparison of thrombin generation for paired-platelet-rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor-VIII inhibitor bypassing agents 47
Peri-operative and post-operative management of haemophiliac patients without inhibitors 45
Ageing successfully with haemophilia : A multidisciplinary programme 44
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study 44
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A 43
Association study between XRCC1 gene polymorphisms and sporadic amyotrophic lateral sclerosis 42
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 41
Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia 41
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study 40
Deep intronic variations may cause mild hemophilia A 40
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders 40
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A : a patient-level meta-analysis 39
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors 39
Arteriovenous fistula as stable venous access in children with severe haemophilia 39
Haemophilia care in children - benefits of early prophylaxis for inhibitor prevention 39
Peri-operative and post-operative management of haemophiliac patients with inhibitors 38
Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases 38
Orthopaedic management of haemophilia arthropathy of the ankle 38
Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura 37
A catastrophic case of skin gangrene 36
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors 36
A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients : evidence for a founder effect 36
X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers 36
Global Emerging HEmophilia Panel (GEHEP): a multinational collaboration for Advancing hemophilia research and treatment 35
Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype 35
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial 35
Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis 35
F8 mRNA studies in haemophilia A patients with different splice site mutations 34
Venous access in haemophilic children: choice and management 34
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A 34
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy 33
Synoviorthesis in haemophilia patients with inhibitors 33
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management 33
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 32
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors 32
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors 31
Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release 31
Congenital afibrinogenemia 31
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study 31
Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors 31
Increased VEGF levels in a case of papillary tumor of the pineal region with intracranial hemorrhage: A potential surrogate indicator of tumor angiogenesis and aggressiveness? 31
Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up 31
Applying a deliberation model to the analysis of consultations in haemophilia: Implications for doctor-patient communication 31
Dental surgery in inherited bleeding disorders with minimal factor support: commentary 31
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease 31
Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs : a review of 116 procedures at a single institution 30
Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients 30
Prevention of arthropathy in haemophilia: prophylaxis 30
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort 30
Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement 30
Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A 30
Integrated postural analysis in children with haemophilia 29
Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry 29
Handwriting Analysis in Children and Adolescents with Hemophilia : A Pilot Study 29
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access 29
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis 28
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study 28
Factor VIII products and inhibitor development in severe hemophilia A 28
Results from a large multinational clinical trial (guardian (TM) 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy 28
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 28
Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients 28
Synovitis and joint health in patients with haemophilia: Statements from a European e‐Delphi consensus study 27
Polypharmacy in older adults with severe haemophilia 27
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C 26
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study 26
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors 25
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing 25
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort 25
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters 24
Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: Considerations on the differentiation between the 2 circulating anticoagulants 23
Radiosynoviorthesis in children with haemophilia 22
PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A 22
Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica 22
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication 21
Investigational drugs for coagulation disorders 21
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study 20
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice 20
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice 20
Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients 20
The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH 20
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors 20
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study 19
Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A 18
The thrombin generation assay distinguishes inhibitor from non‐inhibitor patients with severe haemophilia A 17
Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents 15
Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B 13
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors 13
Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients 13
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis 11
Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications 6
Totale 3.347
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.375
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.375
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202227 0 0 0 7 0 0 2 6 1 3 7 1
2022/202350 12 1 5 4 2 4 0 5 11 6 0 0
2023/202445 2 7 8 1 1 6 0 0 2 0 9 9
2024/202580 8 0 1 2 1 7 4 5 10 30 5 7
2025/20262.663 211 121 278 571 194 85 345 269 236 161 76 116
2026/2027420 260 160 0 0 0 0 0 0 0 0 0 0
Totale 3.353